Utilising the Benefit Risk Assessment of Vaccines (BRAVE) toolkit to evaluate the benefits and risks of Vaxzevria in the EU: a population-based study.

Vaxzevria (ChAdOx1-S recombinant) - University of Oxford, Emergent Biosolutions, Jenner Institute, Barinthus Bio, AstraZeneca

http://www.ncbi.nlm.nih.gov/pubmed/40204579

Catherine Cohet; Chantal Quinten; Daniel R Morales; Geert Molenberghs; Hector Gonzalez Dorta; Johan Verbeeck; Jonas Crèvecoeur; Lander Willem; Neilshan Loedy; Niel Hens; Steven Abrams; Xavier Kurz

Apr 10, 2025